Roche claims court win in haemophilia patent case

Roche said that the Tokyo District Court ruled in favour of its Chugai Pharmaceutical business in a patent litigation case relating to its haemophilia medicine Hemlibra (emicizumab).

“The court ruled that Hemlibra does not infringe patent 4313531, held by Shire’s wholly-owned subsidiaries Baxalta Inc. and Baxalta GmbH,” said Roche.

Reuters reported that Shire’s Baxalta unit has also sued over alleged patent violations in the United States as it seeks to protect haemophilia products put under pressure by Roche’s new drug.